TY - JOUR
T1 - Serum urate as a proposed surrogate outcome measure in gout trials
T2 - From the OMERACT working group
AU - Morillon, Melanie Birger
AU - Christensen, Robin
AU - Singh, Jasvinder A
AU - Dalbeth, Nicola
AU - Saag, Kenneth
AU - Taylor, William J
AU - Neogi, Tuhina
AU - Kennedy, Martin A
AU - Pedersen, Birthe M
AU - McCarthy, Geraldine M
AU - Shea, Beverley
AU - Diaz-Torne, Cesar
AU - Tedeschi, Sara K
AU - Grainger, Rebecca
AU - Abhishek, Abhishek
AU - Gaffo, Angelo
AU - Nielsen, Sabrina Mai
AU - Noerup, Alexander
AU - Simon, Lee S
AU - Lassere, Marissa
AU - Tugwell, Peter
AU - Stamp, Lisa K
AU - Gout Working Group, For The Omeract
N1 - Copyright © 2021 Elsevier Inc. All rights reserved.
PY - 2021/12
Y1 - 2021/12
N2 - Serum urate (SU) is the most common primary efficacy outcome in trials of urate-lowering therapies for gout. Despite this, it is not formally considered a validated surrogate outcome. In this paper we will outline the definitions of biomarkers and surrogate outcome measures, respectively as well as the available frameworks and challenges in the assessment of the validity of serum urate as a surrogate in gout (i.e. a reasonable replacement for gout symptoms).
AB - Serum urate (SU) is the most common primary efficacy outcome in trials of urate-lowering therapies for gout. Despite this, it is not formally considered a validated surrogate outcome. In this paper we will outline the definitions of biomarkers and surrogate outcome measures, respectively as well as the available frameworks and challenges in the assessment of the validity of serum urate as a surrogate in gout (i.e. a reasonable replacement for gout symptoms).
UR - http://www.scopus.com/inward/record.url?scp=85120337109&partnerID=8YFLogxK
U2 - 10.1016/j.semarthrit.2021.11.004
DO - 10.1016/j.semarthrit.2021.11.004
M3 - Review
C2 - 34839932
SN - 0049-0172
VL - 51
SP - 1378
EP - 1385
JO - Seminars in Arthritis and Rheumatism
JF - Seminars in Arthritis and Rheumatism
IS - 6
ER -